Observational studyAnnals of medicine2025
The utility of angiopoietin-2 and blood cell-derived biomarker indices in differentiating rapidly improving acute respiratory distress syndrome (RIARDS) phenotype from persistent-ARDS: a prospective observational study.
Observational study in Annals of medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRapidly improving acute respiratory distress syndrome (RIARDS) is defined as normalization of oxygenation (PaO RESEARCH DESIGN AND
methodsIn this prospective observational study (June 2023-January 2025) at a 2032-bedded tertiary centre, 193 consecutively enrolled mechanically ventilated ARDS patients were assessed. Demographic, clinical, and laboratory data were recorded on Day 1. Plasma Ang-2 was measured using a high-sensitivity ELISA. Primary outcome was RIARDS; secondary outcome was ICU survival.
resultsRIARDS occurred in 18.6% of patients, highest in mild ARDS (52.9%) versus moderate (19.2%) and severe (10.4%). Multivariable regression identified Ang-2 as an independent predictor. A cut-off of 5896 pg/mL yielded an AUC of 0.731 (sensitivity 57.3%, specificity 88.9%). Patients with Ang-2 < 5896 pg/mL were more likely to develop RIARDS (86.1% vs. 13.9%, p-value < 0.001). Kaplan-Meier analysis showed significantly better ICU survival in RIARDS.
conclusionsEarly Ang-2 measurement may help differentiate RIARDS from persistent ARDS, enabling prognostic enrichment and personalized management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.